New vaccination strategies

New vaccination strategies

To the general public, vaccination is one of the most successful medical advances. Nevertheless, there are still numerous infectious diseases for which no vaccine is available. Consequently, at TWINCORE new vaccination strategies are being developed.

Virus-like particles are investigated for utilisation as vaccine vectors, together with the specific in vivo charging of specialised cross-presenting dendritic cells with antigens. One interesting option is the reinforcement of immune responses by influencing regulatory T cells. There are currently comparatively few approved adjuvants for the enhancement of immune responses following vaccination. Therefore, new adjuvants are being investigated in collaboration with partners at HZI. Similarly, investigations are also underway to determine whether cytokines are suitable natural adjuvants for certain vaccination protocols. A further key focus is the analysis of mechanisms that support the induction of long lasting IgG responses.

Highlights

09. March 2017

New perspectives for research on hepatitis C virus

The hepatitis C virus (HCV) infects around 160 million people worldwide. Although there are new therapies, HCV infection is still one of the most common causes of liver transplantation as these new drugs are very expensive and...


16. January 2017

Mode of action of a novel RNA-adjuvants detected – successful collaboration with the CureVac AG

For displaying the full effect, vaccines usually need support - particularly if they are consisting of small peaces of the pathogen. The supporters are called adjuvant and they are normally not part of the pathogen. For most of...


28. January 2016

Neue Immun-Strategie gegen Pneumokokken Infektionen

Streptococcus pneumoniae, landläufig Pneumokokken genannt, sind Bakterien, die eine Vielzahl von schweren Infektionen auslösen. Ihr Krankheiten-Portfolio ist eindrucksvoll: Lungen-, Hirnhaut-, Mittelohr- und...